Elanco Animal Health (ELAN) Stifel Jaws & Paws Conference 2026 summary
Event summary combining transcript, slides, and related documents.
Stifel Jaws & Paws Conference 2026 summary
27 May, 2026Conference overview
The event featured 22 companies, four physician panels, and an animal health industry discussion over two days, with a focus on innovation and market trends in animal health.
Key sessions included updates on product launches, pricing strategies, and market growth across pet and farm animal segments.
Market and industry trends
Animal health market is growing durably, with 7% overall growth last year; farm animal grew 10%, pet 5%.
Pet care spending remains resilient, with consumers prioritizing pet health over other discretionary expenses.
Pricing remains strong and stable, with no significant discounting or price-based competition observed.
Increased investment in direct-to-consumer (DTC) marketing is being used to maintain market share.
Product innovation and launches
New products like Zenrelia and Credelio Quattro are driving growth, with Zenrelia achieving blockbuster status and over 50% U.S. clinic adoption.
Befrena monoclonal antibody launch is underway, with strong early interest from veterinarians and expected to contribute significantly in 2027.
Credelio Quattro is gaining share, now present in 40% of clinics and achieving 53% share within those clinics.
Global expansion of key products is ongoing, including launches in Australia and Japan.
Latest events from Elanco Animal Health
- Q2 2026 saw double-digit revenue growth, margin expansion, and raised full-year guidance.ELAN
Q2 2026 - Innovation and operational efficiency drive growth and margin expansion across pet and farm segments.ELAN
Piper Sandler 37th Annual Healthcare Conference - Innovation pipeline and global reach drive strong growth and raised financial targets.ELAN
46th Annual William Blair Growth Stock Conference - Strong growth, innovation, and all proposals approved, with new blockbusters targeted by 2031.ELAN
AGM 2026 - Innovation and global reach drive strong growth and margin stability in animal health.ELAN
Investor presentation - Q1 2026 revenue up 15% to $1.371B, with raised guidance and strong innovation momentum.ELAN
Q1 2026 - Q1 2025 saw 4% organic growth, raised guidance, and accelerated debt paydown on strong innovation.ELAN
Q1 2025 - Blockbuster launches and innovation pipeline drive strong growth and sustainability in 2025.ELAN
43rd Annual J.P. Morgan Healthcare Conference 2025 - 2024 saw organic growth, margin gains, and debt reduction; 2025 targets innovation-led expansion.ELAN
Q4 2024